Gen-Probe Adds Influenza Tests To Diagnostics Portfolio With Prodesse Buy
This article was originally published in The Gray Sheet
Nucleic acid test maker Gen-Probe will gain a growing pipeline of molecular diagnostics for infectious diseases and add flu tests for the first time through its purchase of privately-held Prodesse, announced Oct. 6
You may also be interested in...
Gen-Probe will double its European sales force and expand its existing molecular diagnostics portfolio through the $132.2 million purchase of UK-based Tepnel Life Sciences
Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.